Burden of systemic glucocorticoid-related complications in severe asthma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Medical Research and Opinion

• Publication date

  2017-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/03007995.2016.1233101PMID 27627132
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma

  2016cited by this paper
• Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.

  2015cited by this paper
• Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use.

  2015cited by this paper
• Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma

  2014cited by this paper
• The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

  2014cited by this paper
• Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation

  2014cited by this paper
• Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

  2014cited by this paper
• Prevalence of oral glucocorticoid usage in the United States: A general population perspective

  2013cited by this paper
• Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus.

  2013cited by this paper
• Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.

  2012cited by this paper
• Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years.

  2011cited by this paper
• Optimal Management of Severe/Refractory Asthma

  2011cited by this paper
• Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.

  2011cited by this paper
• Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry

  2010cited by this paper
• Prednisone, Lupus Activity, and Permanent Organ Damage

  2009cited by this paper
• Asthma and ethnic minorities: socioeconomic status and beyond

  2009cited by this paper
• Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

  2008cited by this paper
• Population disparities in asthma.

  2005cited by this paper
• Acute asthma in adults: a review.

  2004cited by this paper
• The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

  2003cited by this paper
• Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice

  2002cited by this paper
• Damage in systemic lupus erythematosus and its association with corticosteroids.

  2000cited by this paper
• Use of oral corticosteroids in the United Kingdom.

  2000cited by this paper
• The Role of the Propensity Score in Estimating Dose-Response Functions

  2000cited by this paper
• GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

  1996cited by this paper
• Guidelines For The Diagnosis And Management Of Asthma

  1992cited by this paper
• Bioequivalent doses of budesonide and prednisone in moderate and severe asthma.

  1989cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper
• Umbrella Review : Corticosteroid Therapy for Adults ith Acute Asthma

  year unknowncited by this paper

• Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysis

  2025cites this paper
• Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

  2025cites this paper
• Systematic Literature Review of Real-world Outcomes of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.

  2025cites this paper
• Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities

  2025cites this paper
• Characteristics of patients with severe asthma reported to be eligible or non-eligible for biologic therapy in Poland: results from the international observational study RECOGNISE.

  2025cites this paper
• Asthma management, focused on the use of oral corticosteroids: the opinions of Italian asthmatic patients

  2024cites this paper
• Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma

  2024influential citation
• The economic burden of asthma prior to death: a nationwide descriptive study

  2024cites this paper
• Effect of acupoint catgut embedding on p38 MAPK pathway in the lung tissue of asthmatic rats.

  2024cites this paper
• Prevalence, incidence and healthcare burden of eosinophilic granulomatosis with polyangiitis in the UK

  2024cites this paper
• EQUAL ABPA Score 2024: A Tool to Measure Guideline Adherence for Managing Allergic Bronchopulmonary Aspergillosis

  2024cites this paper
• Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma

  2024cites this paper
• Expert Consensus on Oral Corticosteroids Stewardship for the Treatment of Severe Asthma in the Middle East and Africa.

  2024cites this paper
• Burden of eosinophilic granulomatosis with polyangiitis in Europe

  2024cites this paper
• Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study

  2023cites this paper
• Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics

  2023cites this paper
• Severe Asthma Patients: Can We Really Wean Them off of Oral Corticosteroids

  2023cites this paper
• Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

  2023cites this paper
• Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study

  2023cites this paper
• Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma

  2023cites this paper
• Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies

  2022cites this paper
• Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma

  2022cites this paper
• Systemic Corticosteroid-related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal Polyposis.

  2022cites this paper
• Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.

  2022cites this paper
• The prevalence, burden of disease, and healthcare utilization of patients with eosinophilic granulomatosis with polyangiitis in Japan: a retrospective, descriptive cohort claims database study.

  2021cites this paper
• Real world effectiveness of anti-IL5/5R therapy in severe atopic eosinophilic asthma with fungal sensitisation.

  2021cites this paper
• Clinical and Economic Burden of Severe Asthma Among US Patients Treated with Biologic Therapies.

  2021cites this paper
• Uncontrolled Asthma: Unmet Needs in the Management of Patients

  2021cites this paper
• Overcoming Barriers to the Effective Management of Severe Asthma in Italy

  2021cites this paper
• The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review

  2021cites this paper
• A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma.

  2021cites this paper
• The role of systemic corticosteroids in severe asthma and new evidence in their management and tapering

  2021cites this paper
• [Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version].

  2021cites this paper
• Severe asthma: One disease and multiple definitions

  2021cites this paper
• Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis

  2020cites this paper
• Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management

  2020cites this paper
• Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population-based nested case-control studies

  2020cites this paper
• Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

  2020cites this paper
• Characteristics of Specialist‐Diagnosed Asthma‐COPD Overlap in Severe Asthma: Observations from the Korean Severe Asthma Registry (KoSAR)

  2020cites this paper
• STATE OF THE ART Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management

  2020cites this paper
• Trends in oral corticosteroids use in severe asthma: a 14-year population-based study

  2020cites this paper
• Traitements de palier 5 dans l’asthme

  2020cites this paper
• Complications and Health Care Resource Utilization Associated with Systemic Corticosteroids in Children and Adolescents with Persistent Asthma

  2020cites this paper
• Systemic Corticosteroid-Related Complications and Costs in Adults with Persistent Asthma.

  2020cites this paper
• Coexisting COPD Increases Mortality in Patients With Corticosteroid-Dependent Asthma: A Nationwide Population-Based Study

  2020cites this paper
• Prevalence and recovery of adrenal insufficiency in steroid-dependent asthma patients receiving biologic therapy

  2020cites this paper
• Association of low-dosage systemic corticosteroid use with disease burden in asthma

  2020cites this paper
• Treatment of Asthma in Older Adults

  2019cites this paper
• The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database.

  2019cites this paper
• How will nanotechnology lead to better control of asthma?

  2019cites this paper
• Strategies to reduce corticosteroid-related adverse events in asthma

  2019cites this paper
• Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study

  2019cites this paper
• Medication Efficacy and Side Effects in Older Asthmatics

  2019cites this paper
• Future Risks in Patients With Severe Asthma

  2019influential citation
• Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

  2019cites this paper
• Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study

  2018cites this paper
• Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)

  2018cites this paper
• Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

  2018cites this paper
• Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab.

  2018cites this paper
• Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype

  2018cites this paper
• Age and Sex Associations with Systemic Corticosteroid-Induced Morbidity in Asthma.

  2018cites this paper
• Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data

  2018cites this paper
• Age and gender relationships with systemic corticosteroid induced morbidity in asthma: A cross- 1 sectional population-based study of computerised medical records

  2018cites this paper
• A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma

  2018cites this paper
• Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature

  2018influential citation
• Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma.

  2017cites this paper
• The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis

  2017cites this paper